Pharmacogenetic Testing at Community Pharmacy
ConditionPharmacogenetic Testing
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorChantal Csajka
About this trial
The purpose of this study is to assess the clinical impact of reducing treatment failure rates after using genetic information targeting CYP2C19 in validating escitalopram prescription. 5 pharmacies in the canton of Vaud (Lausanne, Switzerland) will participate in the study.
The study will also explored the ability to perform the test in community pharmacy, physician and pharmacist approval of prescription changes, patient acceptance of the test and dose changes, the economic impact of the test, the association between genetic polymorphisms and therapeutic failures and the degree of satisfaction, barriers and facilitators by stakeholders.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Must consent to participate in the study,
Must sign consent,
Must be able to follow and understand the study procedures,
Initiation of escitalopram treatment for unipolar depression with or without anxiety
Disqualifiers
Other condition than depression (such as panic disorder)
Escitalopram treatment already received
Not able to consent to participate in the study.
Trial design
Design model
Parallel
Treatments tested in this trial
Prescription of escitalopram using pharmacogenetic testing
Other interventionAdjustment of escitalopram treatment according to pharmacogenetic results obtained by genetic testing for cytochrome CYP 2C19 (alleles \*2, \*3 and \*17)
Treatment groups
270 Participants
are divided into 2 treatment groupsGroup A: Intervention armOther 1 intervention
Group B: Control armNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Number of participants in the intervention and control groups who experienced a treatment failure on escitalopram.
Number of escitalopram treatment failures in patients with escitalopram prescription based on CYP2C19 genetic testing information versus the control group prior to normal care. Treatment failure is defined here as discontinuation, dose change, or treatment change.
Time frame
From enrollment to last follow-up: circa 3 monthsLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Chantal Csajka
Lead sponsor
Centre Hospitalier Universitaire Vaudois
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: